Researchers at Dana-Farber Cancer Institute have isolated a certain “gene activity signature”, the presence of which indicated a high risk of cancer recurrence in certain breast tumors that have been treated with commonly used chemotherapy drugs.

This also showed resistance to the anthracycline class of drugs according to this Science Daily report.

Though resistant to the anthracycline class of drugs, the kinds of cancers that bear the gene activity signature could still respond to chemotherapy, it was found by the study.

The study has made it possible for oncologists and physicians treating breast cancer to opt for the best possible initial treatment for the breast cancer sufferer rather than use trial and error that may be potentially toxic for the patient.